GreenGro Technologies Announce Plans To Uplist to OTCQB Market
ANAHEIM–GreenGro Technologies, Inc. (OTC PINK: GRNH), a provider of eco-friendly green technologies for the industrial hemp and cannabis industries, today announced that it has initiated its plan to upgrade its position in the public markets and increase its visibility to a wider range of investors through the process of up listing from the OTC Pink Market to the OTCQB Venture Market. As part of this plan, the Company has appointed a new PCAOB-qualified auditor and will be submitting its application to up list to the OTCQB to OTC Markets Group, operator of OTCMarkets.com shortly.
The OTCQB Venture Market, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the U.S. and abroad. Companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. As a verified market with efficient access for U.S. investors, OTCQB helps companies build shareholder value with a goal of achieving a fair market valuation. The quotation of the Company’s common shares on the OTCQB remains subject to the approval of the OTC Markets Group Inc. and the satisfaction of applicable listing requirements.
“With significant growth expected across all our divisions, we believe the Company is ready to up list to the OTCQB Venture Market as part of our overall commitment to improving our accountability, transparency and enhancing shareholder value,” said James Haas, Chairman and Chief Operating Officer of GreenGro Technologies, Inc. “We believe that trading on the OTCQB will increase GreenGro’s visibility to the investment community, in particular to small-cap hedge funds and institutional investors and decrease our overall cost of capital as we continue to solidify our position within the growing cannabis and hemp industries,” concluded Mr. Haas.
(Safe Harbor Act: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.)
(This information is primarily sourced from GreenGro. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Arizona Legislature Seeks to Slash Medical Cannabis Card Prices Amid Declining Sales and Patient Numbers
PHOENIX-- In an effort to revive Arizona's struggling medical cannabis market, lawmakers are pushing forward a bill aimed at reducing the cost of medical cannabis cards. Senate Bill 1466, which received approval from the state ...
New York Regulators Pave the Way for Cannabis Farmers’ Markets Amid Supply Glut
NEW YORK-- In a bid to address the surplus of cannabis products and support local cultivators, regulators in New York have announced plans to introduce cannabis farmers' markets this summer. The move, spearheaded by the ...
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...